Biovector Therapeutics S.A. is staking out turf in the crowded drug delivery field with lipid technology it says will enable it to entrap a wider variety of drugs than conventional liposomes.

The company was to announce today that it has raised $3.7 million in financing from investors Sofinnova, Finovelec, Medical Science Partners, Atlas Venture and TVM Techno Venture Management GmbH & Co. KG. The Ramonville Saint-Agne, France-based company, which just changed its name from A&S Biovecteurs S.A., raised $1.2 million in a previous round of financing in March.